Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Palisade Bio, Inc. (PALI)
Company Research
Source: GlobeNewswire
Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that data from its lead program, PALI-2108, has been selected for poster presentation at Digestive Disease Week® (DDW) 2026, taking place May 2–5, 2026 in Chicago. The Company will be in attendance alongside members of its Clinical Advisory Board (CAB), further reinforcing its engagement with leading experts in inflammatory bowel disease as it advances PALI-2108 toward the clinic. Poster Presentation details are as follows: Session Type: Abstract PosterSession Title: Mechanisms of IBD TherapeuticsTitle: Gut-Targeted PDE4 Inhibition with PALI-2108 Demonstrates Rapid Clinical, Histologic and Biomarker Improvement in U
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile [Yahoo! Finance]Yahoo! Finance
- Palisade Bio (PALI) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Palisade Bio (PALI) is now covered by Wolfe Research. They set an "outperform" rating and a $7.00 price target on the stock.MarketBeat
- Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare ConferenceGlobeNewswire
- Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn's Efficacy Signals [Yahoo! Finance]Yahoo! Finance
PALI
Sec Filings
- 4/17/26 - Form PRE
- 4/2/26 - Form 8-K
- 3/20/26 - Form 10-K
- PALI's page on the SEC website